September 7th 2023
INT230-6 is an investigational product candidate made up of cisplatin, vinblastine, and a penetration enhancer molecule being evaluated for patients with soft tissue sarcoma.
August 11th 2023
Various combination strategies are being explored in soft tissue sarcomas in efforts to increase efficacy.
July 19th 2023
For Sarcoma Awareness Month, Lisa B. Ercolano, MD, and Mark Agulnik, MD, discussed the importance of understanding the genomics of sarcomas and how molecular testing can be useful in this space.
June 25th 2023
Among patients with unresectable or metastatic undifferentiated pleomorphic sarcoma or myxofibrosarcoma, envafolimab generated positive efficacy data with a well-tolerated safety profile.
June 8th 2023
Treatment with INT230-6 alone led to extended survival among patients with soft tissue sarcoma by nearly 450 days, compared with synthetic controls, and demonstrated a favorable safety profile.
Triple Combination of Doxorubicin, Zalifrelimab, and Balstilimab Shows Efficacy and Favorable PFS in Soft Tissue Sarcoma
The combination of doxorubicin, balstilimab, and zalifrelimab has some early signals of activity in both immune hot and cold sarcoma subtypes with manageable toxicity.
Cabozantinib Triplet Shown to be Efficacious Metastatic Soft-Tissue Sarcoma
Correlative work is ongoing following positive results from the phase 1 study of cabozantinib with nivolumab and ipilimumab.
Milademetan and Trabectedin Show Similar Outcomes in Dedifferentiated Liposarcoma
No progression-free survival advantage was shown with milademetan compared with trabectedin in the phase 3 MANTRA study.
Exploring Atezolizumab With or Without Bevacizumab in Alveolar Soft Part Sarcoma
According to Alice P. Chen, MD, the phase 2 study of atezolizumab alone or atezolizumab plus bevacizumab has a unique design.
FDA Places Partial Clinical Hold on Study of FHD-609 in Synovial Sarcoma
A patient treated with the second highest dose level of FHD-609 had a grade 4 adverse event. Enrollment in the study of the agent in patients with synovial sarcoma or SMARCB-1 deleted tumors has been halted.
FDA Grants Orphan Drug Status to TP-1287 for Ewing Sarcoma
TP-1287, an investigational oral phosphate prodrug of the CDK9 inhibitor alvocidib, has been granted an orphan drug designation by the FDA for patients with Ewing sarcoma.
Link Between pCR and Improved Survival for Patients With Soft Tissue Sarcoma
Data from an analysis of the combined NRG-RTOG 0630/9514 trials show that pathologic complete response can be used as a prognostic factor for clinical outcomes in future research of patients with soft tissue sarcoma.
Targeted Therapies Begin to Transform the Treatment of Sarcomas
In an interview with Targeted Oncology, Neeta Somaiah, MD, explained how targeted therapies have started to re-shape the treatment of sarcomas and the potential role of immunotherapy in the future.
Taking on the Challenge to Develop New Therapies for Pediatric Solid Tumors
Both pediatric brain cancers and sarcomas have an extremely dismal outcome in the relapse setting, according to Catherine Bollard, MD. A new Cancer Grand Challenge aims to address the issue with the development of new therapies.
Afami-cel T-Cell Therapy Shows Early Efficacy in Synovial Sarcoma
A phase 1 trial showed efficacy of a novel T-cell therapy targeting MAGE-A4 in solid tumors, particularly synovial sarcoma.
Bringing Targeted Agents from Clinical Trials to the Clinic for Patients With Uterine Sarcoma
In an interview with Targeted Oncology, Matthew A. Ingham, MD, explains the uniqueness of uterine sarcomas and how years of research around these tumors have led to advances in precision medicine for patients.
Intratumoral Injection Shows Antitumor Activity and Safety in Sarcoma
Investigators in the IT-01 trial of INT230-6 as monotherapy or combined with ipilimumab showed safety and potential efficacy in patients with sarcoma.
Afami-cel Elicits Durable Responses With Tolerable Safety in Pre-Treated Synovial Sarcoma
With an overall response rate of 38.6% and a consistent safety profile of that seen in prior trials, afamitresgene autoleucel continues to show clinical responses in patients with late-stage synovial sarcoma.
Camsirubicin Elicits Encouraging Safety/Efficacy Data in Advanced Soft Tissue Sarcoma
Fifty percent of patients with advanced soft tissue sarcoma enrolled in the phase 1b study of camsirubicin and pegfilgrastim had stable disease.
Trial of Seclidemstat in Ewing and FET-Rearranged Sarcomas Pauses Due to Safety Concern
A suspected unexpected serious adverse reaction to seclidemstat led the developer to pause a phase 1/2 evaluating the agent in patients with Ewing and FET-rearranged sarcoma.
Study of Envafolimab +/- Ipilimumab in Undifferentiated Pleomorphic Sarcoma and Myxofibrosarcoma Will Continue
Twelve-week safety data from the phase 2 ENVASARC trial of envafolimab alone and in combination with ipilimumab in patients with undifferentiated pleomorphic sarcoma and myxofibrosarcoma support proceeding with enrollment of patients in the trial.
FDA Grants Orphan Drug Designation to DUNP19 for Osteosarcoma
The FDA has granted an orphan drug designation to DUNP19 for patients with osteosarcoma.
FDA Grants Orphan Drug Designation to AVA6000 in Soft Tissue Sarcoma
The FDA granted an orphan drug designation to AVA6000 for the treatment of patients with soft tissue sarcoma.
Nivolumab and Ipilimumab Shows Promising Responses in Advanced Classical Kaposi Sarcoma
Results from a phase 2 study revealed nivolumab plus ipilimumab to demonstrate promising clinical activity and manageable safety signals in previously treated patients with classical Kaposi sarcoma who had disease progression.
Sarcoma Awareness Month: Helping Patients with Osteosarcoma Requires Multidisciplinary Approach
For sarcoma awareness month, Lisa Ercolano, MD, discusses the need for a multidisciplinary approach to treating patients with osteosarcoma.
FDA Approves Crizotinib for ALK-Positive Inflammatory Myofibroblastic Tumors
The FDA has approved crizotinib as treatment for adult and pediatric patients aged 1 year and older with unresectable, recurrent, or refractory inflammatory ALK-positive myofibroblastic tumors.
Ifosfamide Prolongs Survival in Relapsed/Refractory Ewing Sarcoma
IfIosfamide treatment improved event-free survival compared with topotecan plus cyclophosphamide in patients with relapsed/refractory Ewing sarcoma, phase 2/3 study results show.
Identifying New Biomarkers and Targets in Uterine Sarcomas
With expanding knowledge of the molecular characteristics of uterine sarcomas, investigators are working to develop treatments specific to each subtype.
Selinexor Showed Longer PFS Vs Placebo in Patients with Advanced, Metastatic DD-LPS
Results of the SEAL study revealed a 30% progression-free survival improvement in patients with advanced, metastatic dedifferentiated liposarcoma who underwent selinexor therapy as well as other efficacy and safety benefits.
Pembrolizumab Becomes First Anti-PD-1 Therapy to Show Activity in Kaposi’s Sarcoma
Pembrolizumab may be a new therapeutic option for patients classic and endemic Kaposi’s sarcoma, according to phase 2 study results.
FDA Grants Orphan Drug Designation to Veyonda for Patients With Soft Tissue Sarcoma
Orphan drug designation has been granted to Veyonda as a form of treatment in patients with soft tissue sarcoma.
Promising ICIS Are Explored in Sarcoma, But Disparate Histologies Are Challenging
Patients with sarcoma may respond to treatment with immune checkpoint inhibitors, but identifying patients who are most likely to respond to this therapy is an ongoing obstacle and suggests the need for further research.
GIST Stratification System Needs Further Refinement
There remains a need for biomarkers of primary gastrointestinal stromal tumor subclones to characterize invasion or metastasis, according to Jonathan A. Fletcher, MD.
SPEAR T-Cell Therapy Induces Durable Responses in Synovial Sarcoma and Myxoid/Round Cell Liposarcoma
For patients with advanced synovial sarcoma or myxoid/ round cell liposarcoma, afamitresgene autoleucel is a promising novel therapy.
Ripretinib Stills Holds a Place in the Advanced GIST Landscape After INTRIGUE Study
Results presented during the 2022 January ASCO Plenary Series showed that ripretinib did perform better than sunitinib in terms of the objective response rate, and the safety profile of the drug was favorable compared with sunitinib.
2 Clarke Drive Cranbury, NJ 08512